Autologous NK Cells Combined With GD2 Monoclonal Antibody therapy (Guangzhou Women And Children'S Medical Center)

N/A

Report date: 2025/05/15 20:00:08

Base Information

Drug NameAutologous NK Cells Combined With GD2 Monoclonal Antibody therapy (Guangzhou Women And Children'S Medical Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Antibody-combined cells

Mechanisms of ActionNatural killer cell replacementsAnti-GD2

TargetsDisialoganglioside GD2

Therapy Area/IndicationsNeuroblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesGuangzhou Women And Children'S Medical Center

China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Women And Children'S Medical Center

Inactive CompaniesN/A

Active IndicationsNeuroblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A